Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Prevention of Contrast Induced Nephropathy by Erythropoietin

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2011 by Western Galilee Hospital-Nahariya.
Recruitment status was:  Recruiting
Information provided by:
Western Galilee Hospital-Nahariya Identifier:
First received: May 24, 2011
Last updated: October 9, 2012
Last verified: September 2011

This ia a prospective, randomized, double blind, placebo controlled trial. patients schedule for primary PCI or elective PCI will randomly allocated to receive either a single dose of EPO (Recormon, Roche, Epoetin beta) or saline intravenously before PCI.

The investigators assume that the incidence rate of CIN will be significantly lower in the EPO group compared to placebo. In addition, EPO administration will result in a decrease of infarct size.

Condition Intervention Phase
Chronic Kidney Insufficiency
Drug: Epoetin beta
Drug: Saline 0.9%
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Prevention of Contrast Induced Nephropathy by Erythropoietin in Patients With Diabetes Mellitus and eGFR<60 ml/Min/1.73m2 Undergoing Percutaneous Coronary Intervention

Resource links provided by NLM:

Further study details as provided by Western Galilee Hospital-Nahariya:

Primary Outcome Measures:
  • Incidence of Contrast Induced Nephropathy(CIN) [ Time Frame: 1-3 days after exposure to contrast media ]

Secondary Outcome Measures:
  • Enzymatic infarct size [ Time Frame: 6h and 12 h after exposure to contrast media ]
    Will be measured by Troponin and CK

  • Hospital length of stay [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 3 days ]
  • Renal replacement therapy [ Time Frame: participants will be followed after PCI procedure till discharge, an expected average of 1-2 days ]
  • Hospital mortality [ Time Frame: participants will be followed after PCI procedure till discharge, an expected average of 1-2 days ]

Estimated Enrollment: 142
Study Start Date: August 2011
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Erythropoietin Drug: Epoetin beta
50,000U intravenously
Other Name: Epoietin beta
Placebo Comparator: Placebo Drug: Saline 0.9%
normal saline intravenously
Other Name: Hydration

Detailed Description:

Radiological procedures utilizing intravascular contrast media are being widely applied for both diagnostic and therapeutic purposes. This has resulted in the increasing incidence of procedure-related contrast-induced nephropathy (CIN), which was found to be associated with poor outcome including higher in-hospital mortality rates. Therefore, finding ways to prevent CIN is a valuable clinical and research goal. However, there are no current methods for efficient and cost-effective prevention CIN. Erythropoietin (EPO) has been shown to elicit tissue-protective effects in various experimental models and few clinical studies of acute kidney injury (AKI). Therefore, this prospective, randomized, double blind, placebo controlled trial aim to evaluate, for the first time, the effectiveness of EPO in the prevention of CIN after percutaneous coronary intervention (PCI).

The potential reno-protective effect of EPO is expected to reduce the incidence of the third leading cause of hospital-acquired acute kidney injury. The above together with a cardio-protective effect of EPO is expected to reduce patient's morbidity, mortality and the high health cost associated with CIN treatment.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Over 18 years of age.
  • Diabetic patients.
  • eGFR < 60 ml/min/1.73m2.
  • Scheduled for primary or elective PCI.

Exclusion Criteria:

  • Non diabetic patients.
  • Patients with eGFR ≥ 60 ml/min/1.73m2.
  • Chronic renal replacement therapy.
  • Subject with active malignancy.
  • Subject with any known history of seizure disorders.
  • Subject with polycythemia.
  • Uncontrolled hypertension.
  • Known allergy or hypersensitivity to EPO.
  • Use of EPO 1 week prior to randomization.
  • Use of long acting EPO (CERA) during 1 month prior to randomization.
  • Use of NAC or bicarbonate during 3 days prior to randomization.
  • Contrast media exposure during the last 7 days before randomization.
  • Pregnant or lactating women.
  • Participation in other clinical trial.
  • Refusal or inability to give informed consent due to mental or physical state.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01364402

Contact: Lilach Shema-Didi, RN, MPH 972-507887538
Contact: Lilach Shema-Didi, RN, MPH

Western Galilee Hospital Recruiting
Nahariya, Israel
Contact: Shaul Atar, MD   
Contact: Batya Kristal, MD   
Principal Investigator: Shaul Atar, MD         
Principal Investigator: Batya Kristal, MD         
Sub-Investigator: Lilach Shema-Didi, RN, MPH         
Sub-Investigator: Irith Weissman, MD         
Sub-Investigator: Ronit Geron, MD         
Sponsors and Collaborators
Western Galilee Hospital-Nahariya
Principal Investigator: Shaul Atar, MD Western Galilee Hospital
  More Information

Responsible Party: Dr. Shaul Atar, Western Galilee Hospital Identifier: NCT01364402     History of Changes
Other Study ID Numbers: EPO1
Study First Received: May 24, 2011
Last Updated: October 9, 2012

Keywords provided by Western Galilee Hospital-Nahariya:
scheduled for PCI

Additional relevant MeSH terms:
Renal Insufficiency, Chronic
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Epoetin Alfa
Hematinics processed this record on April 26, 2017